Form 8-K - Current report:
SEC Accession No. 0001213900-25-119217
Filing Date
2025-12-08
Accepted
2025-12-08 16:00:25
Documents
13
Period of Report
2025-12-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0268667-8k_inmune.htm   iXBRL 8-K 24758
2 AMENDMENT NO. 5 TO RIGHTS AGREEMENT, DATED AS OF DECEMBER 5, 2025, BETWEEN THE C ea026866701ex4-1_inmune.htm EX-4.1 16295
  Complete submission text file 0001213900-25-119217.txt   211048

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE inmb-20251205.xsd EX-101.SCH 3017
4 XBRL LABEL FILE inmb-20251205_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE inmb-20251205_pre.xml EX-101.PRE 22360
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0268667-8k_inmune_htm.xml XML 3682
Mailing Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432
Business Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432 8589643720
Inmune Bio, Inc. (Filer) CIK: 0001711754 (see all company filings)

EIN.: 475205835 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38793 | Film No.: 251556045
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)